Inform Genomics Selects US Oncology Research as the Site Management Organization (SMO) for Pivotal Multicenter Study of OnPART Boston, MA, May 29, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to discover and develop genomic-based, precision medicine...

Inform Genomics Selects Vector Oncology as Contract Research Organization (CRO) for Pivotal Multicenter Study of OnPART Boston, MA and Memphis, TN, May 29, 2015 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a privately held company that utilizes a proprietary analytic platform to develop genomic-based, precision medicine...

Inform Genomics Presents Results for OnPART(tm) Showing High Degree of Accuracy Predicting Six Common Side Effects of FOLFOX Chemotherapy for Colon Cancer Boston, MA, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Inform Genomics, Inc., a private company focused on developing novel platforms of genomic-based personalized medicine products for cancer supportive...